

Serplulimab ASTRUM-005

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Serplulimab ASTRUM-005

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Serplulimab in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Experimental Arm: Serplulimab + Carboplatin + Etoposide

Control Arm: Placebo + Carboplatin + Etoposide



